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Abstract
BACKGROUND—No single standard treatment exists for patients with small, node-negative, 
human epidermal growth factor receptor type 2 (HER2)–positive breast cancers, because most of 
these patients have been ineligible for the pivotal trials of adjuvant trastuzumab.
METHODS—We performed an uncontrolled, single-group, multicenter, investigator-initiated 
study of adjuvant paclitaxel and trastuzumab in 406 patients with tumors measuring up to 3 cm in 
greatest dimension. Patients received weekly treatment with paclitaxel and trastuzumab for 12 
weeks, followed by 9 months of trastuzumab monotherapy. The primary end point was survival 
free from invasive disease.
RESULTS—The median follow-up period was 4.0 years. The 3-year rate of survival free from 
invasive disease was 98.7% (95% confidence interval [CI], 97.6 to 99.8). Among the 12 relapses 
seen, 2 were due to distant metastatic breast cancer. Excluding contra-lateral HER2-negative 
breast cancers and nonbreast cancers, 7 disease-specific events were noted. A total of 13 patients 
(3.2%; 95% CI, 1.7 to 5.4) reported at least one episode of grade 3 neuropathy, and 2 had 
symptomatic congestive heart failure (0.5%; 95% CI, 0.1 to 1.8), both of whom had normalization 
of the left ventricular ejection fraction after discontinuation of trastuzumab. A total of 13 patients 
had significant asymptomatic declines in ejection fraction (3.2%; 95% CI, 1.7 to 5.4), as defined 
by the study, but 11 of these patients were able to resume trastuzumab therapy after a brief 
interruption.
CONCLUSIONS—Among women with predominantly stage I HER2-positive breast cancer, 
treatment with adjuvant paclitaxel plus trastuzumab was associated with a risk of early recurrence 
of about 2%; 6% of patients withdrew from the study because of protocol-specified adverse 
events. (Funded by Genentech; ClinicalTrials.gov number, NCT00542451.)
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Overexpression of the human epidermal growth factor receptor type 2 (HER2) occurs in 
approximately 15 to 20% of invasive breast cancers and was historically associated with 
poor clinical outcomes.1–4 Trastuzumab, a humanized monoclonal antibody that binds 
HER2, improves the outcomes for patients with HER2-positive breast cancer. Four phase 3 
randomized trials involving more than 8000 patients showed that when trastuzumab was 
administered in combination with or after chemotherapy, the risk of recurrence was 
decreased by approximately 50% and overall survival improved.5–9 These trials focused 
largely on patients with stage II or stage III HER2-positive breast cancers.
Although patients with stage I HER2-positive tumors are expected to derive a smaller 
absolute benefit from adjuvant therapy than those with larger or node-positive tumors, they 
remain at more than minimal risk for a recurrence of breast cancer.10–14 However, given the 
more limited benefit from adjuvant treatment in these patients, the decision to use 
trastuzumab and chemotherapy is influenced by the toxicity of the treatment regimen.
Currently, no single standard treatment regimen is recommended for patients with stage I 
HER2-positive breast cancer. We conducted a single-group, multicenter, investigator-
initiated study to characterize the prospective outcomes in a group of patients uniformly 




Enrollment required a pathological diagnosis of adenocarcinoma of the breast, with 
immunohistochemical staining for the HER2 protein of 3+ intensity or amplification of the 
HER2 gene on fluorescence in situ hybridization (ratio of HER2 to chromosome 17 
centromere [CEP17], ≥2.0). The invasive tumor had to measure no more than 3 cm in the 
greatest dimension; there was no lower limit on tumor size. Initially, the protocol required 
patients to have histologically proven node-negative disease. The protocol was amended to 
allow entry of patients who had one lymph-node micrometastasis if an axillary dissection 
was completed and no further lymph-node involvement was detected. Other requirements 
included adequate hematopoietic and liver function and a left ventricular ejection fraction of 
50% or greater. The institutional review board at each participating institution approved the 
study. Written informed consent was provided by all the participants.
The study was designed by the first author and the last two authors. The data were collected 
by the Dana–Farber Cancer Institute and analyzed by the lead and assistant statisticians (the 
second and the fifteenth authors, respectively) in collaboration with the first and last authors, 
both of whom vouch for the completeness and accuracy of the data and analyses and for the 
fidelity of the study to the protocol. No one who was not an author contributed to the writing 
of the manuscript. Genentech provided funding for the study but did not provide paclitaxel 
or trastuzumab; these agents were commercially supplied, and the costs were billed to 
insurance companies. The protocol is available with the full text of this article at NEJM.org.
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Treatment consisted of the intravenous administration of 80 mg of paclitaxel per square 
meter of body-surface area weekly for 12 weeks and a loading dose of 4 mg of intravenous 
trastuzumab per kilogram of body weight on day 1, followed by 2 mg per kilogram weekly, 
for a total of 12 doses. After the completion of 12 weeks of treatment with trastuzumab, the 
dosing of trastuzumab could be continued on a weekly basis, or the regimen could be 
changed to 6 mg per kilogram every 3 weeks for 40 weeks to complete a full year of 
intravenous treatment with trastuzumab.
Patients who underwent lumpectomy were required to receive either partial-breast radiation, 
which was performed before the initiation of the protocol therapy, or radiation of the whole 
breast, which was initiated after the completion of treatment with paclitaxel. Treatment with 
trastuzumab was continued during the time the patient was receiving radiation therapy. 
Adjuvant hormonal therapy was recommended for women with hormone-receptor–positive 
tumors after the completion of paclitaxel therapy.
ASSESSMENT OF CARDIAC FUNCTION
The protocol required assessment of the left ventricular ejection fraction with 
echocardiography or multigated acquisition scanning at baseline and at 12 weeks, 6 months, 
and 1 year after the start of protocol therapy. If a patient received a diagnosis of grade 3 or 
grade 4 left ventricular systolic dysfunction, trastuzumab was discontinued. Interruption of 
dosing with trastuzumab was required if either of the following conditions was met: a 
decrease in the ejection fraction of 10 to 15 percentage points from baseline, with the 
ejection fraction at least 1 percentage point below the lower limit of the normal range at the 
radiology facility in which the assessment was performed; or a decrease of 16 or more 
percentage points from baseline. If either of these conditions was met, another assessment of 
ejection fraction was required after 4 weeks; if the ejection fraction did not increase 
substantially and two consecutive interruptions in the protocol therapy were required, the 
patient was withdrawn from the study treatment.
STATISTICAL ANALYSIS
The primary measure of efficacy was the number of events of invasive disease (recurrence 
and new invasive disease) and death from any cause, as defined by the standardized efficacy 
end-points (STEEP) criteria.15 We used a group-sequential Poisson test that was based on 
the total patient-years of follow-up. In designing the trial, a 3-year event rate of 9.2% was 
deemed to be unacceptable in this patient population. In contrast, a 3-year rate of invasive 
disease of 5% would be considered to be successful, and the study was powered to have a 
95% probability of rejecting the null hypothesis. The planned sample size was 400 patients. 
Two interim analyses for futility were scheduled after accrual of 225 and 800 patient-years, 
with a final analysis conducted after accrual of 1600 total patient-years of follow-up. If 39 or 
fewer events of invasive disease were observed at the time of the final analysis, the regimen 
would be considered to be effective. Overall one-sided type I and type II errors of 0.05 were 
controlled in a group-sequential design by means of a Pocock-style error-spending function 
for beta that is constrained by the exact Poisson distribution.
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Estimation of the survival and of cumulative probability functions for survival free from 
invasive disease was performed by means of the Kaplan–Meier product-limit method; 
confidence boundaries were calculated on the log-scale with the use of Greenwood’s 
formula for the variance. Planned subgroup analyses were performed in strata defined 
according to tumor size (≤1 cm or >1 cm) and hormone-receptor status (with a positive 
status defined as staining of 1% or more of either the estrogen receptor or the progesterone 
receptor on immunohistochemical analysis). The analyses of the incidence of adverse 
events, including planned analyses of cardiac toxicity and neurotoxicity of grade 3 or higher, 
were reported with 95% confidence intervals from the binomial distribution. In an 
amendment to the protocol, the follow-up period was extended to 10 years for all patients. 




A total of 410 patients were enrolled in the study between October 9, 2007, and September 
3, 2010 (see Table S1 in the Supplementary Appendix, available at NEJM.org); 406 of these 
patients began the protocol therapy (Fig. 1). The data and safety monitoring board at the 
Dana–Farber/Harvard Cancer Center reviewed data on toxicity on a semi-annual basis. The 
first interim analysis was performed at 167 patient-years, before the target accrual was 
reached, and the subsequent interim analysis was performed after the accrual of 841 patient-
years. On the basis of the strength of the data at the second analysis, the study team asked 
the board to consider early release of the data from a third interim analysis, which was 
performed after accrual of 1316 patient-years. The board released the data to the study team, 
and the results were initially presented after accrual of 1435 patient-years. The results shown 
here are from all data available as of April 21, 2014, including 1605 patient-years of follow-
up, and represent the final analysis.
PATIENTS
The median age of patients in the study was 55 years (range, 24 to 85). A total of 272 
patients (67.0%) had hormone-receptor–positive disease. Among these patients, 62.2% had 
tumors that measured 1 cm or less in the greatest dimension, and 68.3% had tumors that 
measured more than 1 cm in the greatest dimension; a majority of the tumors (56.2%) were 
high-grade. In the total study population, 49.5% of the patients had tumors that measured 1 
cm or less (stages T1mic [≤0.1 cm], T1a [>0.1 to ≤0.5 cm], and T1b [>0.5 to ≤1.0 cm]); 
8.9% of the patients had tumors that measured between 2 and 3 cm (stage T2). Six patients 
(1.5%) had nodal micrometastases (Table 1).
Among the 406 patients who began the protocol therapy, 356 (87.7%) completed all 52 
weeks of therapy; 24 discontinued therapy because of protocol-specified toxic effects, and 6 
patients discontinued because of other toxic effects. By the time of the final analysis, 29 
patients had left the study: 2 patients died from causes unrelated to breast cancer (0.5%), 17 
patients withdrew consent (4.2%), and 10 were lost to follow-up (2.5%) (Fig. 1). The 
median follow-up time was 4.0 years; the maximum follow-up period was 6.2 years.
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A total of 12 patients had invasive disease events or died (Table 2): 2 had distant metastases 
(one of which was HER2-negative), 4 had local or regional recurrences, 4 had contralateral 
breast cancer (3 of whom had HER2-negative breast cancer), 1 died from a rapidly 
progressive primary ovarian cancer, and 1 died from a stroke after participating in the study 
for 71 months. Four patients had an event that was not considered to be a relapse of invasive 
disease (second, nonbreast primary cancers in the bladder, thyroid, or lung), and data for 
these patients were censored at the date of diagnosis of the second cancer; 4 patients 
received a diagnosis of ductal carcinoma in situ (an event not categorized as a relapse of 
invasive disease) and continue to be followed for relapse of invasive disease. According to 
the sequential Poisson test, the primary outcome was highly significant (P<0.001). The 
Kaplan–Meier plot and the 95% confidence interval for survival free from invasive disease 
(Fig. 2A) show a 3-year rate of 98.7% (95% confidence interval [CI], 97.6 to 99.8). Patient 
outcomes even exceeded the 95% 3-year rate of survival free from invasive disease that 
defined success in powering the study to reject the null hypothesis (uncorrected Poisson 
model, P<0.001).
The duration of the recurrence-free interval (which, unlike recurrence-free survival, did not 
include death from cancer other than breast cancer) according to standardized efficacy end 
points15 was considered to be an exploratory end point. Six patients had a local or regional 
recurrence or a distant recurrence or died from breast cancer (Table 2). The 3-year rate of 
recurrence-free survival was 99.2% (95% CI, 98.4 to 100) (Fig. 2B). Survival curves in 
subgroups defined according to tumor size (≤1 cm vs. >1 cm) and hormone-receptor status 
(positive vs. negative) (Fig. 2C and 2D) showed that the rate of recurrence in these 
subgroups was lower than anticipated (the lower boundaries of the 95% confidence interval 
for survival free of invasive disease at 3 years in the subgroups exceeded 96.0%).
ADVERSE EVENTS
During 12 weeks of combined therapy, 13 patients (3.2%; 95% CI, 1.7 to 5.4) reported at 
least one grade 3 episode of neuropathy. No grade 4 neurotoxic effects were reported (0%; 
95% CI, 0 to 0.9). Two patients (0.5%; 95% CI, 0.1 to 1.8) had grade 3 systolic dysfunction 
of the left ventricle (symptomatic congestive heart failure) during active therapy — at 6 
months and 11 months — and both recovered after the discontinuation of trastuzumab. A 
clinically significant asymptomatic decline in ejection fraction (as defined in the protocol) 
that led to an interruption in treatment with trastuzumab occurred in 13 patients (3.2%; 95% 
CI, 1.7 to 5.4); in 2 of these patients, the ejection fraction did not normalize, and the patients 
were unable to complete the remaining year of trastuzumab therapy. A total of 7 patients had 
grade 3 or grade 4 allergic reactions to the study treatment, and only 1 of these patients was 
able to complete treatment. Alopecia was expected in the vast majority of patients; data 
regarding its incidence were not collected. Other specified toxic effects reported during the 
52 weeks of protocol therapy are summarized in Table 3.
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Two controversies affect the management of stage I HER2-positive breast cancer. The first 
involves defining the threshold for initiating systemic therapy. Guidelines from the National 
Comprehensive Cancer Network (NCCN) suggest that adjuvant chemotherapy with 
trastuzumab should be considered in patients with small, node-negative tumors, including 
patients with T1bN0 tumors (with N0 denoting no regional lymph-node involvement), but 
the NCCN acknowledges that such patients are generally not included in randomized trials 
of adjuvant therapy.16 The second controversy relates to the determination of the safest and 
most effective regimen, bearing in mind the potential for considerable toxic effects with 
chemotherapy and trastuzumab and the generally favorable outcomes in women with very 
small tumors. Many physicians recommend treatment regimens such as doxorubicin, 
cyclophosphamide, paclitaxel, and trastuzumab (ACTH) or docetaxel, carboplatin, and 
trastuzumab (TCH). These regimens are associated with substantial toxic effects and are 
commonly used in patients who have a much higher risk of disease recurrence, according to 
the results of randomized trials.5–8 These studies enrolled a limited number of patients with 
stage I breast cancer. In the joint analysis, only 5.7% of patients had node-negative disease.8 
Both the Herceptin Adjuvant (HERA) study (2 years vs. 1 year of adjuvant trastuzumab for 
HER2-positive breast cancer) and the Breast Cancer International Research Group 006 
(BCIRG-006) study included greater numbers of node-negative patients, including a limited 
number of patients with stage I disease.6,7 Only the BCIRG-006 study allowed the 
enrollment of patients with node-negative tumors measuring less than 1 cm in the greatest 
dimension.
In our trial, we administered adjuvant therapy prospectively only in patients with small, 
node-negative, HER2-positive tumors and used a treatment regimen similar to ACTH, but 
omitting doxorubicin and cyclophosphamide. The results suggest a low risk of cancer 
recurrence (less than 2% at 3 years) with a regimen in which the rate of serious toxic effects 
was low (with an incidence of heart failure that was only 0.5%).
The results must be considered in the context of several studies that have examined the risk 
of disease recurrence in patients who have not received trastuzumab or, in most cases, 
chemotherapy. The limitations of these studies are clear; they included a modest number of 
patients, and there were biases inherent to their retrospective designs. The largest of the 
studies focused on 520 patients in the NCCN database who had small HER2-positive 
cancers (tumors up to 1 cm in the greatest dimension).10 The 5-year rate of survival free 
from distant recurrence was 94% for patients with T1bN0 hormone-receptor–negative 
tumors, 93% for T1aN0 hormone-receptor–negative tumors, and 94 to 96% for patients with 
T1a–bN0 hormone-receptor–positive disease. A study from the M.D. Anderson Cancer 
Center suggests that among 98 patients with T1a–bN0 HER2-positive tumors, the 5-year 
rate of recurrence-free survival was 77.1%, and the 5-year rate of survival free from distant 
recurrence was 86.4%.11 In a study of 117 node-negative, HER2-positive tumors measuring 
up to 2 cm in the greatest dimension in a tumor registry in British Columbia, Canada, the 10-
year rate of relapse-free survival was 68.3% among patients with hormone-receptor–
negative tumors and 77.5% among patients with hormone-receptor–positive tumors.17 
Although recurrence rates vary across these studies, the rates range from approximately 5 to 
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30%, with distant recurrences occurring in as many as 20% of patients with tumors 
measuring up to 1 cm in the greatest diameter. The studies consistently suggest that the risk 
of recurrence, at least in the first 5 years, is higher in the hormone-receptor–negative group 
than in the hormone-receptor–positive group.
The median follow-up for patients in our trial is only 4.0 years, but the benefits that were 
observed in the initial published reports of the randomized trials of adjuvant trastuzumab-
based chemotherapy were maintained with additional follow-up. The study population in our 
trial had a higher proportion of hormone-receptor–positive tumors (67%) than did the 
populations in the pivotal adjuvant trastuzumab studies (51 to 54%),5–7 although the 
proportion of hormone-receptor–positive tumors in our trial is consistent with that reported 
in some studies involving women with small, node-negative tumors. The higher frequency 
of hormone-receptor–positive tumors in our study could have implications for late 
recurrence, and all patients will be followed for 10 years to facilitate a comprehensive 
description of patient outcomes. Because the influence of chemotherapy on the risk of 
recurrence is generally most notable during the first several years after diagnosis,18 it seems 
unlikely that a different chemotherapy regimen administered with trastuzumab would affect 
the risk of late recurrence.
We recognize that a prospective, randomized trial would have been the best option. 
However, we did not believe that such a design would have been feasible given the 
accumulating evidence from retrospective studies. Patients and their providers may have 
been unlikely to enroll in a trial that included a group in which patients would not receive 
trastuzumab. Some clinicians and investigators might have argued for a trial of trastuzumab 
alone versus trastuzumab plus chemotherapy, but there are limited data indicating that 
trastuzumab alone is an effective approach.19–21 Instead, we opted for a regimen of 
trastuzumab plus chemotherapy that would be associated with fewer toxic effects than the 
established regimens for patients with a higher risk of recurrence.
The regimen we used in this study was associated with patient outcomes that were better 
than expected on the basis of historical data. However, the study does not provide data to 
support the use of trastuzumab-based chemotherapy in all patients with small HER2-positive 
tumors, and there will be many patients with T1a disease and some with T1b disease who 
will decide with their physicians to avoid the toxic effects of a trastuzumab-based regimen.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 2. Probabilities of Disease-free Survival and Recurrence-free Interval
Panel A shows the probability of disease-free survival in the intention-to-treat population, 
and Panel B the recurrence-free interval in the intention-to-treat population (unlike 
recurrence-free survival, the recurrence-free interval did not include death from cancer other 
than breast cancer). The shading in Panels A and B denotes the 95% confidence intervals. 
Panel C shows the probability of disease-free survival according to tumor size, and Panel D 
the probability of disease-free survival according to hormone-receptor (HR; estrogen 
receptor or progesterone receptor) status. Tick marks represent the time of censoring for 
patients who were recurrence-free.
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Table 1
Baseline Characteristics of the Patients.*
Characteristic Patients (N = 406)
no. (%)
Age group
 <50 yr 132 (32.5)
 50–59 yr 137 (33.7)
 60–69 yr 96 (23.6)
 ≥70 yr 41 (10.1)
Sex
 Female 405 (99.8)
 Male 1 (0.2)
Race†
 White 351 (86.5)
 Black 28 (6.9)
 Asian 11 (2.7)
 Other 16 (3.9)
Primary tumor
 Size
  T1mic: ≤0.1 cm 9 (2.2)
  T1a: >0.1 to ≤0.5 cm 68 (16.7)
  T1b: >0.5 to ≤1.0 cm 124 (30.5)
  T1c: >1.0 to ≤2.0 cm 169 (41.6)
  T2: >2.0 to ≤3.0 cm 36 (8.9)
 Nodal status
  N0 400 (98.5)
  N1mic 6 (1.5)
 Histologic grade
  I: well-differentiated 44 (10.8)
  II: moderately differentiated 131 (32.3)
  III: poorly differentiated 228 (56.2)
  Unknown 3 (0.7)
 HER2-positive status 406 (100)
 Estrogen-receptor status
  Positive 260 (64.0)
  Negative 141 (34.7)
  Borderline 5 (1.2)
 Progesterone-receptor status
  Positive 201 (49.9)
  Negative 196 (48.3)
  Borderline 8 (2.0)
  Unknown 1 (0.2)
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Characteristic Patients (N = 406)
no. (%)
 Hormone-receptor status
  Positive 272 (67.0)
  Negative 134 (33.0)
*
Percentages may not total 100 because of rounding. HER2 denotes human epidermal growth factor receptor type 2, N0 no regional lymph-node 
involvement, and N1mic lymph-node involvement with tumor larger than 0.2 mm in diameter but smaller than 2 mm.
†
Race was self-reported.
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Table 2
Events Observed for the Primary End Point of Disease-free Survival.
Event Patients (N = 406) Time to Event
no. (%) mo
Any recurrence or death 12 (3.0)
Local or regional recurrence*
 Ipsilateral axilla, HER2-positive 3 (0.7) 12, 20, 54
 Ipsilateral breast, HER2-positive 1 (0.2) 37
New contralateral primary breast cancer
 HER2-positive 1 (0.2) 56
 HER2-negative 3 (0.7) 12, 37, 59
Distant recurrence*
 Skeletal tissue, HER2-positive 1 (0.2) 27
 Soft tissue, HER2-negative 1 (0.2) 46
Death
 Breast-cancer–related 0
 Not breast-cancer–related 2 (0.5) 13, 71
*
These events were included in the calculation of the recurrence-free interval.
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Table 3
Most Common Adverse Events Occurring during Protocol Therapy.
Event Maximum Grade Total
Grade 2 Grade 3 Grade 4
number of patients (percent)
Fatigue 81 (20.0) 9 (2.2) 0 90 (22.2)
Diarrhea 47 (11.6) 6 (1.5) 0 53 (13.1)
Neuropathy 39 (9.6) 14 (3.4) 0 53 (13.1)
Neutropenia 26 (6.4) 15 (3.7) 2 (0.5) 43 (10.6)
Hyperglycemia 35 (8.6) 7 (1.7) 0 42 (10.3)
Leukopenia 28 (6.9) 10 (2.5) 0 38 (9.4)
Allergic reaction 28 (6.9) 6 (1.5) 1 (0.2) 35 (8.6)
Elevated alanine amino-transferase level 23 (5.7) 7 (1.7) 0 30 (7.4)
Anemia 28 (6.9) 1 (0.2) 0 29 (7.1)
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